NASH Accelerated Approval: US FDA Remains Confident In Pathway For Liver Disease

 
• By Michael McCaughan

A two-day workshop on potential biomarkers in NASH provided a forum for US FDA officials to offer implicit reassurance to drug developers: the agency stands behind its guidance on Accelerated Approval for the liver disease, despite the rejection of the first application seeking to use that approach.

MASH-NASH
NASH (non-alcoholic steatohepatitis) is now also known as MASH (metabolic dysfunction associated steatohepatitis). • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Review Pathways

More from Pathways & Standards